GlassScriptPhysician profile
Mathew J Brakora
NPI 1013989177
$2,430.04
in general payments reported to CMS, 2019-2025
20 companies · $69.43 in 2025
The $69.43 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $354 · 2021: $285 · 2022: $204 · 2023: $537 · 2024: $297 · 2025: $69.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812 · Education: $90.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.88 |
| Education | $90.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $388.52 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $364.34 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $254.38 | 2019-2023 | |
| Pfizer INC. | $237.57 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $211.66 | 2020-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $203.42 | 2020-2023 | Andexxa |
| Mylan Specialty L.P. | $153.75 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.68 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $92.00 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Glaxosmithkline, LLC. | $90.72 | 2023 | Arexvy |
| Novartis Pharmaceuticals Corporation | $89.51 | 2019 | |
| Horizon Therapeutics Plc | $45.35 | 2022 | |
| Abbvie INC. | $29.92 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $25.30 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.63 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.04 | 2023 | Linq II |
| Inspire Medical Systems, INC. | $17.86 | 2025 | Inspire |
| Boston Scientific Corporation | $13.66 | 2021 | |
| Gilead Sciences, INC. | $13.36 | 2021 | |
| Advanced Respiratory, INC | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Brakora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.